Dr Reddy's Laboratories reported Q1 2027 revenue of INR8,071 crores (USD853 million), declining 5.6% year-over-year but growing 7.4% sequentially. The company's EBITDA margin stood at 12.5%, impacted by semaglutide API-related challenges; excluding this impact, the margin was 15.4%. North America revenue fell 41% year-over-year to $236 million but grew 19% sequentially. Emerging markets revenue increased 31% year-over-year to INR1,833 crores, whilst India revenue rose 17% to INR1,780 crores. The company maintained a net cash surplus of INR3,057 crores (USD323 million). Dr Reddy's launched several complex generic products, including Bosutinib in the United States and semaglutide in Canada and India.

Novo Nordisk's obesity drug Wegovy wins India approval to fight silent fatty liver killer. ET Online Last Updated: Jul 17, 2026, 02:18:00 PM IST India's drug regulator approved Novo Nordisk's Wegovy for MASH treatment. This drug targets a serious progressive form of fatty liver disease. The approval follows a committee recommendation for adults with moderate to advanced liver fibrosis. Wegovy, containing semaglutide, was previously approved for chronic weight management. This marks a significant expansion for the blockbuster obesity drug in India. Novo Nordisk said on Friday that India's drug regulator has approved its blockbuster obesity drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a serious and progressive form of fatty liver disease. The Central Drugs Standard Control Organisation (CDSCO) has approved Wegovy's 2.4 mg semaglutide injection for the treatment of MASH, the Danish drugmaker said. The approval follows a recommendation by the CDSCO's Subject Expert Committee (SEC) on Endocrinology and Metabolism, which had cleared the drug for adults with noncirrhotic MASH with moderate to advanced liver fibrosis, at stages F2 to F3, during a meeting held on April 23, 2026. You May Like MASH, formerly known as nonalcoholic steatohepatitis (NASH), is caused by a buildup of fat in the liver that can lead to inflammation and liver damage. The condition is part of a broader spectrum of fatty liver disease and can progress to more severe complications, including cirrhosis and liver failure, if left untreated. Novo Nordisk said about two in three people in India have fatty liver disease, underscoring the country's large potential patient population. The company described it as a silent disease, noting that people often do not experience symptoms until it has progressed to an advanced stage. Wegovy contains the active ingredient semaglutide and was first approved in India on April 20, 2022, for chronic weight management, before Friday's expanded approval for the liver condition. The drug is already approved in multiple markets for weight management, and had previously secured MASH approvals abroad, including in the US in August 2025, where it became the first and only GLP-1 receptor agonist approved to treat adults with MASH with moderate to advanced liver scarring, excluding cirrhosis, and in Canada, where it received conditional marketing authorization as the first and only treatment for adults with non-cirrhotic MASH. The US approval was based on Part 1 of the ESSENCE trial, which showed a statistically significant improvement in liver fibrosis with no worsening of steatohepatitis, along with resolution of steatohepatitis without worsening of fibrosis, compared with placebo. Novo has been vying for a share of India's fast-growing obesity-drug market against Eli Lilly's Mounjaro and lower-cost generic semaglutide products launched by local drugmakers such as Dr Reddy's and Sun Pharma. The company sold about 76,000 units of Wegovy in India in the first six months of 2026, according to data from market researcher Pharmarack. Read More News on

HiveMinds secures integrated digital mandate for Dr. Reddy's select OTC and butrition brands. June 15, 2026 HiveMinds, a part of the Madison Group, has secured the integrated digital marketing mandate for Dr. Reddy's Laboratories (Dr. Reddy's), a global pharmaceutical company. The mandate is aimed at strengthening digital presence, accelerating e-commerce growth, and enhancing consumer engagement across channels for Dr. Reddy's select over-the-counter (OTC) and nutrition brands. As part of the mandate, HiveMinds will provide an integrated digital strategy, including full-funnel e-commerce management across channels and creative services to drive impactful consumer experiences. The mandate will be managed by HiveMinds Mumbai team, with a focus on optimising the consumer journey, improving performance metrics, and delivering data-driven, high-impact creative solutions. Deepti Bhaduria, CEO, HiveMinds said, "Health and wellness is a very interesting space for digital today, and Dr. Reddy's has already built strong consumer relevance across categories. We're excited to partner with them at this stage of their growth journey. "With our strength in commerce, creative and experimentation, we believe we can help scale customer acquisition meaningfully and build a strong digital engine for the brand," Bhaduria added.